With half its patients from Asia and only 13% from North America, the Destiny Breast 11 trial's results may not be fully generalizable to US patients. Differences in metabolism, healthcare systems, and side effect reporting across regions can impact outcomes, a key consideration when interpreting global trial data.

In the TROPION-Breast02 trial, a survival benefit for Dato-DXD was seen mainly in regions without later-line access to TROP2 ADCs. Western patients often received an ADC second-line, muting the first-line survival difference and showing how post-progression therapy access can confound trial results.

The global patient population in the pivotal DESTINY-Breast09 trial had less prior exposure to modern agents like pertuzumab and T-DM1 than is typical in Western clinics. This context is crucial when applying the trial's results to more heavily pre-treated populations.

In pivotal ADC trials like ASCENT-03 and 04, over 80% of patients in the control (chemotherapy) arm received the ADC upon progression. This high crossover rate makes interpreting overall survival (OS) data difficult, as the control group's outcomes are artificially improved by subsequent access to the novel drug.

In clinical practice, the choice between competing post-neoadjuvant antibody-drug conjugate (ADC) trials is often driven by the practical reality of which study is open and geographically accessible, rather than a clear biological signal suggesting one ADC is superior.

In the ASCENT-07 trial, investigators may have prematurely switched patients from the standard chemotherapy arm to superior, commercially available ADCs at the first hint of progression. This real-world practice can mask an experimental drug's true benefit on progression-free survival.

An overall survival (OS) benefit in an adjuvant trial may not be meaningful for patients in systems (e.g., the U.S.) with guaranteed access to the same effective immunotherapy upon recurrence. The crucial, unanswered question is whether treating micrometastatic disease is inherently superior to treating macroscopic disease later, a distinction current trial data doesn't clarify.

The phase 3 trial for luspatercept narrowly missed its primary endpoint because of an unusually high placebo response in the Asia-Pacific region, especially China. After a single patient's data was re-adjudicated, the p-value became significant, highlighting how operational factors and regional practices can mask a drug's true efficacy in global trials.

The STARGLO trial (glofitamab-gemox) showed a strong survival benefit in Asia-Pacific patients but not in the small North American cohort. This geographic discrepancy, with only 9% of patients from the US, was a key reason the FDA did not approve the combination, while European agencies did.